HCPCS code J8510 – Oral busulfan, 2 mg per unit

Found our content helpful?

Key takeaways

J8510 describes busulfan (Myleran) oral 2 mg, and each billed unit equals 2 mg dispensed

Medicare Part B covers J8510 under oral anti-cancer parity when the IV form would also be covered. Medical necessity must be documented per the MAC’s LCD

Reimbursement follows ASP methodology and changes quarterly, so verify the current CMS ASP file before submitting

Medicaid requires NDC reporting on J8510 claims. Medicare Part B does not mandate it, though some MACs request it

Pabau’s claims management software supports J-code billing workflows and tracks claim status end to end

What is HCPCS code J8510?

HCPCS code J8510 is the Healthcare Common Procedure Coding System Level II code for busulfan, administered orally, billed in 2 mg increments. CMS maintains J8510 in the oral anti-cancer drug J-code range, and the code is active and billable. Both the short and long descriptors read “Busulfan; oral, 2 mg.”

Oral chemotherapy codes sit between pharmacy benefit management and Part B drug policy, which is where J8510 gets misrouted. Coders unfamiliar with oral anti-cancer parity sometimes send busulfan to Part D, and the denial then takes weeks to unwind.

Drug overview: Busulfan (Myleran) oral 2 mg

Busulfan is a bifunctional alkylating chemotherapy agent that cross-links DNA strands and disrupts replication in rapidly dividing cells. The FDA has approved oral busulfan for two indications. It is used for palliative treatment of chronic myelogenous leukemia (CML), and for conditioning before hematopoietic stem cell transplantation (HSCT), usually alongside cyclophosphamide.

Busulfan carries an FDA Black Box Warning for severe, life-threatening myelosuppression. This guide covers billing only and is not dosing or clinical guidance.

• Drug class: Alkylating agent
• Brand name: Myleran (oral tablets)
• FDA-approved indications: Chronic myelogenous leukemia (CML); conditioning regimens before HSCT
• Route: Oral (tablet)
• Dosage unit for billing: 2 mg per J8510 unit
• Related IV code: J0594 (busulfan, injection, 1 mg) for intravenous formulations

The distinction between oral busulfan (J8510) and injectable busulfan (J0594) matters at the claim level. Submitting J8510 for an IV dose, or J0594 for a tablet, triggers a route-mismatch denial. Confirm the route of administration against the pharmacy dispensing record before you pick the code.

Medicare coverage and reimbursement for J8510

Medicare Part B covers J8510 under the oral anti-cancer treatment parity provision. That provision requires Part B to cover an oral anti-cancer drug at the same level as its intravenous equivalent. It applies where both formulations are medically accepted for the same indication.

Injectable busulfan (J0594) is covered under Part B, so oral busulfan qualifies for parity coverage on the same FDA-approved indications. Coverage is not automatic on every claim. Three conditions must be satisfied, and the third one changes by contractor.

• Medical necessity documentation: The diagnosis must be an FDA-approved indication for busulfan (CML or HSCT conditioning). The patient record must reflect that indication. LCD requirements vary by MAC.
• Part B enrollment: The prescribing physician must be enrolled in Medicare. The dispensing entity, whether a practice or a pharmacy, must also be enrolled as a supplier.
• Formulary alignment: Some MACs publish local coverage determinations specifying acceptable ICD-10-CM diagnosis codes. Confirm with the relevant MAC before dispensing.

Reimbursement is based on Average Sales Price (ASP) plus a percentage add-on, consistent with CMS Part B drug payment policy. ASP rates are updated quarterly by CMS. Citing a rate from a prior quarter on a current claim frequently leads to audit flags. Pull the current ASP file from CMS’s physician fee schedule search each quarter, and put that pull on the billing calendar.

J8510 fee schedule

Because ASP rates change quarterly, the table below shows the structure of J8510 fee schedule data rather than a fixed dollar figure. Always verify the current allowed amount against the live CMS ASP quarterly file before submitting claims.

Tracking electronic remittance advice (ERA) for J8510 claims is the fastest way to catch ASP underpayments before they pile up. Practice management software like Pabau tracks each J-code claim from submission to payment posting, with claims management built into the same patient record.

How to bill J8510: Step-by-step guide

A paid J8510 claim turns on four things. Those are the unit count, the diagnosis, the NDC where the payer wants one, and the place of service. The seven steps below follow an oral chemotherapy dispense in a practice setting.

Route, units, and the payer’s NDC rule are where the claim is won or lost, so check them in that order.

1. Verify the dispensed quantity. Confirm the total milligrams dispensed from the pharmacy record. Divide by 2 to get the number of J8510 units. Example: 4 mg dispensed = 2 units billed.
2. Select a supporting ICD-10-CM code. The diagnosis must be an FDA-approved indication. Common codes: C92.10 (CML, BCR/ABL-positive, not in remission) or Z79.899 (long-term use of other medication) as a secondary. See the ICD-10 section below for the full list.
3. Report the NDC (Medicaid claims). Use the 11-digit NDC in the qualifier NQ format on CMS-1500 (loop 2410, LIN segment on 837P). Include the unit of measure qualifier and quantity.
4. Determine place of service. Outpatient infusion center or physician office: POS 11 or 22. Hospital outpatient: UB-04 claim type, revenue code 0636 (drugs requiring specific identification) with J8510 in the HCPCS field.
5. Add any required modifiers. Review the modifier rules in the section below, then append the ones your MAC requires before submission.
6. Submit via 837P (professional) or UB-04 (institutional). Confirm the ordering physician NPI is in field 17 (CMS-1500) or in the appropriate 837P loop. A charge entry that carries every required field cuts scrubbing rejections at the clearinghouse.
7. Monitor claim status. Expect an ERA within 14–30 days for Medicare Part B. Flag adjudication codes indicating coverage parity review for follow-up. Keep a J8510-specific denial queue so parity reviews do not sit unworked.

Applicable modifiers for HCPCS code J8510

CMS built its JW and JZ modifier policy around single-dose vials with measurable waste. Oral busulfan is dispensed in multi-tablet bottles, so that logic does not transfer cleanly.

Whether waste-reporting modifiers apply to a tablet depends on current CMS guidance and, in some cases, on MAC policy. Confirm the requirement with your MAC before you append one.

ICD-10 diagnosis codes used with J8510

Every J8510 claim requires at least one ICD-10-CM diagnosis code that supports medical necessity for busulfan. The diagnosis must align with an FDA-approved indication and, where a MAC LCD exists, must appear on the covered diagnosis list. Using an off-label or unsupported ICD-10 code is the second most frequent cause of J8510 denials after incorrect units.

Confirm each code against your MAC’s LCD coverage list before submission. Some local determinations specify remission status qualifiers or require the transplant status code as a secondary. Our ICD-10-CM code index is the place to check a neighboring diagnosis before you commit to one. Document the clinical rationale in the patient record to support the selected code.

NDC reporting requirements for J8510

NDC (National Drug Code) reporting rules differ between Medicare and Medicaid, and mixing them up is a frequent source of J8510 claim errors.

To report the NDC for busulfan oral correctly on an 837P claim, use the 11-digit NDC in the 5-4-2 format. Leading zeros must be included. The unit of measure is typically “UN”, meaning each tablet.

Cross-reference the dispensed package’s label for the exact NDC, since different manufacturers and package sizes carry different NDC numbers. Using an NDC from a prior dispense that no longer matches the current package will cause a validation mismatch.

Documentation requirements for J8510 claims

A J8510 claim is only as strong as the record behind it. Payers ask for documentation when parity coverage is reviewed, and the request usually arrives months after the dispense.

• Medical necessity: The chart must name the FDA-approved indication being treated, either CML or conditioning before HSCT. A diagnosis code alone does not carry this.
• The prescription and dispensing record: Keep the ordering physician’s NPI, the prescribed dose in milligrams, and the quantity dispensed. The unit count on the claim has to match this record exactly.
• LCD criteria: Where your MAC publishes a local coverage determination for oral anti-cancer drugs, note in the chart which criteria were met. Some MACs then expect modifier KX on the claim.
• The NDC and package label: Record the 11-digit NDC from the package you dispensed, along with the manufacturer and package size.
• Prior authorization and ABN: File the payer’s authorization number where one was required. Keep the signed Advance Beneficiary Notice where the indication may fall outside coverage.

Hold these records for the retention period your state and payer contracts require. An audit that lands two years later is answered from the chart, not from memory.

Related HCPCS and oral chemotherapy codes

Busulfan billing staff frequently need to reference sibling codes when crosswalking between routes of administration or when billing combination conditioning regimens. The table below covers the most commonly referenced codes in an oncology billing workflow that includes J8510.

The AAPC’s HCPCS code lookup is a useful free reference for confirming descriptors and checking code-specific billing notes. For HCPCS Level II structure and maintenance, the CMS HCPCS overview is the definitive source.

If a conditioning regimen sends you to the cyclophosphamide side of the claim, our guide to J9070 covers the replacement codes in detail.

Common billing errors and how to avoid them

Five errors account for most avoidable J8510 denials. Oncology coders juggle weight-based dosing cycles, multi-drug regimens, and parity coverage conditions at once, which is where they creep in.

• Incorrect unit count. Billing 1 unit for a 4 mg dose. J8510 equals 2 mg per unit, so always divide total mg dispensed by 2. The figure on the claim must match the pharmacy dispensing record line for line.
• Wrong code (J8510 vs J0594). J8510 is oral only. Selecting J0594 for an oral dispense, or J8510 for an IV administration, triggers a route-mismatch denial at adjudication.
• Missing or malformed NDC on Medicaid claims. Medicaid rejects J8510 claims without a valid 11-digit NDC in the 5-4-2 format. The NDC must match the package dispensed, so copying last month’s number from a different manufacturer package will fail validation.
• Unsupported ICD-10-CM code. Submitting a diagnosis code that is off-label for busulfan, such as a hematologic malignancy outside the MAC’s LCD, results in a medical necessity denial. Confirm coverage against the MAC’s active LCD before dispensing.
• Duplicate billing with J0594. Practices that offer both oral and IV busulfan on the same date of service sometimes submit J8510 and J0594 together. Payers treat that as a duplicate. Bill only the code matching the route administered.

Flag J8510 as a high-attention code in your denial workflow. Unit calculation and parity coverage give it two failure points, and both are caught in a pre-submission scrub.

How Pabau keeps the unit count and the record in step

Most oncology billing teams run J8510 through three disconnected places. The dose lives in the pharmacy log, the diagnosis lives in the chart, and the unit count gets typed into the claim by hand.

Pabau keeps the dispense record, the diagnosis, and the claim on one patient record. The charge line pulls the dispensed milligrams straight from the record, so the unit count is calculated rather than retyped.

Claim status and ERA postings land in the same place, with denial reasons attached to the claim they came from. A parity review is then answered from the chart that produced the claim.

The result is fewer unit-count corrections, faster parity appeals, and a shorter list of J-code claims nobody has chased. Every Pabau subscription includes the billing tools, so nothing here sits behind a higher tier.

Simplify J-code billing from charge entry to ERA posting

Pabau’s claims management tools give oncology billing teams visibility across every step, from J-code submission to payment reconciliation. See how Pabau handles oral chemotherapy billing workflows.

Book a demo

Conclusion

J8510 is a small code with an exacting set of rules. The unit math is trivial, but it only works if the number on the claim comes from the dispensing record rather than the prescription.

Build the three checks into a pre-submission scrub and the denial pattern changes within a quarter. Leave them to the coder’s memory and busulfan claims will keep coming back, one parity review at a time.

Book a demo to see how Pabau tracks a J8510 claim from the dispensing record through to the ERA.

Continue your research

Want to see what happens to a J8510 claim after you hit submit? How a medical claims clearinghouse works explains the electronic validation steps between submission and adjudication.

Need your charge capture to feed the claim cleanly? Superbill guide for medical practices covers the fields to structure so unit counts and diagnoses travel together.

Working a J8510 denial queue? Denial management in healthcare sets out how to triage, rework, and resubmit without losing the appeal window.

Want fewer drug claims coming back at all? What makes a clean claim lists the checks that get a claim paid on first submission.

Reporting on where the money stalls between dispense and payment? Revenue cycle management explained shows which stages to measure first.

Frequently asked questions